Serial No.:

Filed:

Dkt. 0575/61136/JPW/AJM/AJD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Andrew R. Marks and Steven O. Marx Applicants:

January 22, 2001 P27 PREVENTS CELLULAR MIGRATION For:

09/766,944

1185 Avenue of the Americas New York, New York 10036

Examiner: Alana M. Harris

November 30, 2005

Art Unit: 1642

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. \$1.97(b)(4) to supplement the Information Disclosure Statements filed April 20, 2001, May 24, 2002, October 27, 2004 and April 4, 2005 in connection with the aboveidentified application.

In accordance with their duty of disclosure under 37 C.F.R. \$1.56, applicants direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (Exhibit A), and attached hereto as Exhibits 1-6:

- 1. International Publication No. WO 02/056753 A2, published July 25, 2002 (Exhibit 1);
- Marx, S.O. and Marks, A.R. (2001) Bench to bedside: the 2. development of rapamycin and its application to stent restenosis. Circulation 104: 852-855 (Exhibit 2);
- Seasholtz, T.M., Majumdar, M., Kaplan, D.D. and Brown, J.H. 3. (1999) Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration.

Applicants: Andrew R. Marks and Steven O. Marx

Serial No.: 09/766,944

Filed: January 22, 2001

Page 2

Circ. Res. 84: 1186-1193 (Exhibit 3);

4. Sun, J., Marx, S.O., Chen, H.J. et al. (2001) Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration. Circulation 103: 2967-2972 (Exhibit 4);

- 5. Vidal, A., Millard, S.S., Miller, J.P. and Koff, A. (2002) Rho activity can alter the translation of p27 mRNA and is important for Ras^{V12}-induced transformation in a manner dependent on p27 status. J. Biol. Chem. 277: 16433-16440 (Exhibit 5); and
- 6. Yoshioka, K., Nakamori, S. and Itoh, K. (1999)
 Overexpression of small GTP-binding protein RhoA promotes
 invasion of tumor cells. Cancer Res. 59: 2004-2010
 (Exhibit 6).

The Examiner is respectfully requested to make this reference of record in the present application by initialing and returning a copy of the enclosed Form PTO-1449.

Applicants note that the above-listed references were previously cited in a Supplementary Partial European Search Report issued in connection with European Patent Application No. 03760397.4, a foreign counterpart of the subject application. A copy of the Supplementary Partial European Search Report is attached hereto as **Exhibit B**.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Pursuant to 37 C.F.R. \$1.97(b)(4), no fee is deemed necessary in

Applicants:

Andrew R. Marks and Steven O. Marx

Serial No.:

09/766,944

Filed:

January 22, 2001

Page 3

connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313, 1450

Alan J. Morrison Reg. No. 37,399 30/0/ Date Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

U.S. Department of Commerce Application Number Form PTO-09/766,944 Patent and Trademark Office Filing Date January 22, 2001 First Named Inventor Andrew R. Marks Art Unit DISCLOSURE STATEMENT 1642 (Use several sheets if necessary) Examiner Name Alana M. Harris Attorney Docket No. 61136/JPW/AJM/AJD U.S. PATENT DOCUMENTS Examiner Cite **Document Number** Date Name of Patentee or Applicant of Cited Document Number-Kind Code^{2 (if known)} No.1 Initials MM-DD-YYYY FOREIGN PATENT DOCUMENTS Name of Patentee or Applicant of Cited **Foreign Patent Document Country** Examiner Cite Publication Document Code³⁻Number⁴⁻Kind Code^{5 (if kn)} Initials No.1 Date MM-DD-YYYY WO 02/056753 A2 07-25-2002 The Trustees 1 of Columbia University in the City of New York NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, Initials No. city and/or country where published. Marx, S.O. and Marks, A.R. (2001) Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104: 852-855; Seasholtz, T.M., Majumdar, M., Kaplan, D.D. and Brown, J.H. (1999) Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ. Res. 84: 1186-1193; Sun, J., Marx, S.O., Chen, H.J. et al. (2001) Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration. Circulation 103: 2967-2972; Vidal, A., Millard, S.S., Miller, J.P. and Koff, A. (2002) Rho activity can alter the translation of p27 mRNA and is important for Ras^{V12}-induced transformation in a manner dependent on p27 status. J. Biol. Chem. 277: 16433-16440; and Yoshioka, K., Nakamori, S. and Itoh, K. (1999) Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res. 59: 2004-2010.

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

DATE CONSIDERED

EXAMINER SIGNATURE

Applicants: Andrew R. Marks et al. U.S. Serial No.: 09/766,944

Filed: January 22, 2001

Exhibit A